Survival Outcomes in Resected Extrahepatic Cholangiocarcinoma: Effect of Adjuvant Radiotherapy in a Surveillance, Epidemiology, and End Results Analysis

Published:October 25, 2010DOI:


      The benefit of adjuvant radiotherapy (RT) after surgical resection for extrahepatic cholangiocarcinoma has not been clearly established. We analyzed survival outcomes of patients with resected extrahepatic cholangiocarcinoma and examined the effect of adjuvant RT.

      Methods and Materials

      Data were obtained from the Surveillance, Epidemiology, and End Results (SEER) program between 1973 and 2003. The primary endpoint was the overall survival time. Cox regression analysis was used to perform univariate and multivariate analyses of the following clinical variables: age, year of diagnosis, histologic grade, localized (Stage T1-T2) vs. regional (Stage T3 or greater and/or node positive) stage, gender, race, and the use of adjuvant RT after surgical resection.


      The records for 2,332 patients were obtained. Patients with previous malignancy, distant disease, incomplete or conflicting records, atypical histologic features, and those treated with preoperative/intraoperative RT were excluded. Of the remaining 1,491 patients eligible for analysis, 473 (32%) had undergone adjuvant RT. After a median follow-up of 27 months (among surviving patients), the median overall survival time for the entire cohort was 20 months. Patients with localized and regional disease had a median survival time of 33 and 18 months, respectively (p < .001). The addition of adjuvant RT was not associated with an improvement in overall or cause-specific survival for patients with local or regional disease.


      Patients with localized disease had significantly better overall survival than those with regional disease. Adjuvant RT was not associated with an improvement in long-term overall survival in patients with resected extrahepatic bile duct cancer. Key data, including margin status and the use of combined chemotherapy, was not available through the SEER database.
      To read this article in full you will need to make a payment
      ASTRO Member Login
      ASTRO Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology™. Hepatobiliary Cancers. Version 2.2008. Available from: Accessed May 4, 2008.

        • Blumgart L.H.
        • Thompson J.N.
        The management of malignant strictures of the bile duct.
        Curr Probl Surg. 1987; 24: 69-127
        • Heron D.E.
        • Stein D.E.
        • Eschelman D.J.
        • et al.
        Cholangiocarcinoma: The impact of tumor location and treatment strategy on outcome.
        Am J Clin Oncol. 2003; 26: 422-428
        • Sako K.
        • Seitzinger G.L.
        • Garside E.
        Carcinoma of the extra-hepatic bile ducts: Review of the literature and report of six cases.
        Surgery. 1957; 41: 416-437
        • Jang J.Y.
        • Kim S.W.
        • Park D.J.
        • et al.
        Actual long-term outcome of extrahepatic bile duct cancer after surgical resection.
        Ann Surg. 2005; 241: 77-82
        • Jarnagin W.R.
        Cholangiocarcinoma of the extrahepatic bile ducts.
        Semin Surg Oncol. 2000; 19: 156-176
        • Stain S.C.
        • Baer H.U.
        • Dennison A.R.
        • et al.
        Current management of hilar cholangiocarcinoma.
        Surg Gynecol Obstet. 1992; 75: 579-588
        • Hanna S.S.
        • Rider W.D.
        Carcinoma of the gallbladder or extrahepatic bile ducts: The role of radiotherapy.
        Can Med Assoc J. 1978; 118: 59-61
        • Oh D.
        • Lim do H.
        • Heo J.S.
        • et al.
        The role of adjuvant radiotherapy in microscopic tumor control after extrahepatic bile duct cancer surgery.
        Am J Clin Oncol. 2007; 30: 21-25
        • D'Angelica M.I.
        • Jarnagin W.R.
        • Blumgart L.H.
        Resectable hilar cholangiocarcinoma: Surgical treatment and long-term outcome.
        Surg Today. 2004; 34: 885-890
        • Moertel G.C.
        Extrahepatic bile duct.
        in: Holland J.F. Frei III, E. Cancer medicine. 2nd ed. Lea & Febiger, Philadelphia1982 (1785–1990)
        • Boerma E.J.
        Research in the results of resection of the hilar bile duct cancer.
        Surgery. 1990; 108: 572-580
        • Alden M.E.
        • Waterman F.M.
        • Topham A.K.
        • et al.
        Cholangiocarcinoma: Clinical significance of tumor location along the extrahepatic bile duct.
        Radiology. 1995; 197: 511-516
        • Minsky B.D.
        • Wesson M.F.
        • Armstrong J.G.
        • et al.
        Combined modality therapy of extrahepatic biliary system cancer.
        Int J Radiat Oncol Biol Phys. 1990; 18: 1157-1163
        • Wakai T.
        • Shirai Y.
        • Moroda T.
        • et al.
        Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma.
        Cancer. 2005; 103: 1210-1216
        • Pitt H.A.
        • Nakeeb A.
        • Abrams R.A.
        • et al.
        Perihilar cholangiocarcinoma: Postoperative radiotherapy does not improve survival.
        Ann Surg. 1995; 221: 788-798
      2. The Surveillance, Epidemiology, and End Results (SEER) Program, accessing SEER data. National Cancer Institute. Available from: Accessed January 10th, 2008.

      3. Hamilton S.R. Aaltonen H.L. World Health Organization classification of tumors: pathology and genetics of tumors of the digestive system. IARC Press, Lyon, France2000
      4. The R Project for Statistical Computing. R version 2.8.1. R Foundation for Statistical Computing; 2009. Available from: Accessed March 21, 2008.

        • Cameron J.L.
        • Pitt H.A.
        • Zinner M.J.
        • et al.
        Management of proximal cholangiocarcinomas by surgical resection and radiotherapy.
        Am J Surg. 1990; 159: 91-98
        • Flickinger J.C.
        • Epstein A.H.
        • Iwatsuki D.
        • et al.
        Radiation therapy for primary carcinoma of the extrahepatic biliary system: An analysis of 63 cases.
        Cancer. 1991; 68: 289-294
        • Alden M.E.
        • Mohiuddin M.
        The impact of radiation dose in combined external beam and intraluminal IR-192 brachytherapy for bile duct cancer.
        Int J Radiat Oncol Biol Phys. 1994; 28: 945-951
        • Schoenthaler R.
        • Phillips T.L.
        • Castro J.
        • et al.
        Carcinoma of the extrahepatic bile ducts: the University of California at San Francisco experience.
        Ann Surg. 1994; 219: 267-274
        • Hayes Jr., J.K.
        • Sapozink M.D.
        • Miller F.J.
        Definitive radiation therapy in bile duct carcinoma.
        Int J Radiat Oncol Biol Phys. 1988; 15: 735-744
        • Oberfield R.A.
        • Rossi R.L.
        The role of chemotherapy in the treatment of bile duct cancer.
        World J Surgery. 1988; 12: 105-108
        • Ben-David M.A.
        • Griffith K.A.
        • Abu-Isa E.
        • et al.
        External-beam radiotherapy for localized extrahepatic cholangiocarcinoma.
        Int J Radiat Oncol Biol Phys. 2006; 66: 772-779
        • Todoroki T.
        • Ohara K.
        • Kawamoto T.
        • et al.
        Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma.
        Int J Radiat Oncol Biol Phys. 2000; 46: 581-587
        • Shinohara E.T.
        • Mitra N.
        • Guo M.
        • et al.
        Radiotherapy is associated with improved survival in adjuvant and palliative treatment of extrahepatic cholangiocarcinomas.
        Int J Radiat Oncol Biol Phys. 2009; 74: 1191-1198
        • Borghero Y.
        • Crane C.H.
        • Szklaruk J.
        • et al.
        Extrahepatic bile duct adenocarcinoma: Patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone.
        Ann Surg Oncol. 2008; 15: 3147-3156
        • Macdonald J.S.
        Gastric cancer—New therapeutic options.
        N Engl J Med. 2006; 355: 76-77
        • Macdonald J.S.
        • Smalley S.R.
        • Benedetti J.
        • et al.
        Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
        N Engl J Med. 2001; 345: 725-730
        • Kapiteijn E.
        • Marijnen C.A.
        • Nagtegaal I.D.
        • et al.
        Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.
        N Engl J Med. 2001; 345: 638-646
        • Shinohara E.T.
        • Mitra N.
        • Guo M.
        • et al.
        Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma.
        Int J Radiat Oncol Biol Phys. 2009; 72: 1495-1501
        • Nelson J.W.
        • Ghafoori A.P.
        • Willett C.G.
        • et al.
        Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma.
        Int J Radiat Oncol Biol Phys. 2009; 73: 148-153
        • Kamada T.
        • Saitou H.
        • Takamura A.
        • et al.
        The role of radiotherapy in the management of extrahepatic bile duct cancer: An analysis of 145 consecutive patients treated with intraluminal and/or external beam radiotherapy.
        Int J Radiat Oncol Biol Phys. 2002; 54: 414-419


      Commenting Guidelines

      To submit a comment for a journal article, please use the space above and note the following:

      • We will review submitted comments as soon as possible, striving for within two business days.
      • This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
      • We require that commenters identify themselves with names and affiliations.
      • Comments must be in compliance with our Terms & Conditions.
      • Comments are not peer-reviewed.